BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Nov 4, 2025 • 11min
BIO-Europe 2025: Barcelona based Connecta Therapeutics is moving its neuroplasticity modulator for fragile X syndrome into a phase 2a study after completing first in human studies late last year
CEO Jordi Fàbrega and CFO Josep Prous discusses the asset, CTH120, which is a NCE and proprietary to Connecta.
Nov 3, 2025 • 10min
BIO-Europe 2025: Switzerland based ReproNovo is focused on reproductive health - with two clinical stage assets and three indications it is going after
CEO Jean Marie Duvall describes the company's programs, one focused on male inferitliy and another that may have dual purposes of helping with embryo implantation and adenomyosis. She says to make sure there is a clear commercial path if when you focus on this field.
Nov 3, 2025 • 11min
BIO-Europe 2025: Anavo Therapeutics is focused on phosphatases - and is publicly talking about its two lead programs for the first time
CEO Birgit Zech and CSO Edward Holson discuss the unique beginning of the company (a powerpoint deck), and the difficulties in drugging phosphatases. Plus, the company is now disclosing two indications/targets in development.
Nov 3, 2025 • 10min
BIO-Europe 2025: Herantis Pharma is developing HER-096 for Parkinson's, a blood-brain-barrier penetrant small peptide molecule that is designed to mimic the activity of CDNF
CEO Antti Vuolanto walks us through recent phase 1b data, which reported safety and PK data. Biomarker data will be forthcoming before the end of the year.
Nov 3, 2025 • 17min
BIO-Europe 2025: Valneva's partner Pfizer has been running a big trial of a Lyme disease vaccine that has covered the last three seasons - it will read out in the first part of next year
Valneva CEO Thomas Lingelbach walks us through this program by describing how the vaccine is designed and how the study has been conducted. Plus, his comments on FDA's rescinding of the company's Chikungunya virus vaccine.
Nov 3, 2025 • 16min
Roche will pay Manifold Bio $55M up front, and up to $2B in biobucks, to collaborate on multiple next-generation brain shuttles for neurological diseases
Manifold Co-Founders Gleb Kuznetsov and Pierce Ogden explain how Manifold is working on next generation shuttles, which means going beyond transferrin. They discuss the deal, and also Manifold's broader platform of high-throughput, in-vivo discovery work.
Nov 3, 2025 • 10min
BIO-Europe 2025: ReNewVax CEO Neil Murray believes the antigens the company has found will enable it to develop a pneumococcal vaccine that targets all ca.100 existing variants
He describes the unmet need for a better vaccine than those already on the market, and says he is looking for a lead investor for a series A at BIO-Europe.
Nov 3, 2025 • 13min
BIO-Europe 2025: Abivax CEO Marc de Garidel discusses physician and payor feedback after obefazimod's phase 3 UC induction readouts, and next steps regarding maintenance and Crohn's
He describes the mechanism of the therapy, as well the data and commercial landscape for UC. Plus, how he thinks about combos and business development.
Nov 3, 2025 • 11min
BIO-Europe 2025: AAVantgarde Bio, which is working on gene therapies for inherited retinal diseases that are caused by mutations in large genes, closed a $141M series B raise today
CEO Natalia Misciattelli describes the lead programs for Stargardt Disease and Usher 1B Syndrome, and how AAVantgarde is able to solve the problem of delivering genes that are naturally too large for single AAV vectors.
Oct 31, 2025 • 24min
Mathai Mammen recaps the first clinical data Parabilis Medicines reported on its beta-catenin program earlier this month at EMSO and AACR-NCI-EORTC 2025. Plus, degraders for prostate cancer, and more.
He explains the company's "Helicon" peptide platform, and why he believes it is well suited to target previously undruggable problems like beta-catenin. Then he discusses clinical presentations on this program in multiple tumor types, and preclinical data on two degrader programs for prostate cancer.
